title: Formulation strategies for sustained release of proteins.
abstract: Proteins constitute an increasing proportion of the drugs in development. The barriers to their entry into the blood stream and rapid clearance means that they often have to be injected several times a day, affecting patient compliance. This paper reviews the major technologies enabling the development of injectable sustained-release products and formulation strategies to maintain protein integrity and modify release rates. Whilst many injectable sustained-release products are on the market, these are all delivering small molecular weight drugs and peptides. This is due to the manufacturing processes that denature and degrade the proteins upon encapsulation and release into the body. Formulation strategies are discussed and a number of new technologies reviewed that are able to overcome the issues with conventional manufacturing processes. The reliance of many processes on organic solvents has prevented their application to the development of injectable sustained release protein products. The development of entirely solvent free and aqueous methods of manufacture of these products has meant that numerous sustained-release protein products are close to reaching the market.
authors: Critical Pharmaceuticals Limited, BioCity Nottingham, Pennyfoot Street, Nottingham NGI IGF, UK. andrew.lewis@criticalpharmaceuticals.com
authors: Andrew L
authors: AL
authors: Lewis
authors: Lisbeth
authors: L
authors: Illum
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004355:Drug Stability; D006801:Humans; D007267:Injections; D011489:Protein Denaturation; D011506:Proteins / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D003692:Delayed-Action Preparations; D011506:Proteins